RESUMEN
In 1999, French legislators asked health insurance funds to develop a système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) [national health insurance information system] in order to more precisely determine and evaluate health care utilization and health care expenditure of beneficiaries. These data, based on almost 66 million inhabitants in 2015, have already been the subject of numerous international publications on various topics: prevalence and incidence of diseases, patient care pathways, health status and health care utilization of specific populations, real-life use of drugs, assessment of adverse effects of drugs or other health care procedures, monitoring of national health insurance expenditure, etc. SNIIRAM comprises individual information on the sociodemographic and medical characteristics of beneficiaries and all hospital care and office medicine reimbursements, coded according to various systems. Access to data is controlled by permissions dependent on the type of data requested or used, their temporality and the researcher's status. In general, data can be analyzed by accredited agencies over a period covering the last three years plus the current year, and specific requests can be submitted to extract data over longer periods. A 1/97th random sample of SNIIRAM, the échantillon généraliste des bénéficiaires (EGB), representative of the national population of health insurance beneficiaries, was composed in 2005 to allow 20-year follow-up with facilitated access for medical research. The EGB is an open cohort, which includes new beneficiaries and newborn infants. SNIIRAM has continued to grow and extend to become, in 2016, the cornerstone of the future système national des données de santé (SNDS) [national health data system], which will gradually integrate new information (causes of death, social and medical data and complementary health insurance). In parallel, the modalities of data access and protection systems have also evolved. This article describes the SNIIRAM data warehouse and its transformation into SNDS, the data collected, the tools developed in order to facilitate data analysis, the limitations encountered, and changing access permissions.
Asunto(s)
Bases de Datos Factuales/normas , Sistemas de Registros Médicos Computarizados , Programas Nacionales de Salud , Práctica de Salud Pública/normas , Toma de Decisiones , Francia , Humanos , Sistemas de Registros Médicos Computarizados/organización & administración , Sistemas de Registros Médicos Computarizados/normas , Programas Nacionales de Salud/organización & administración , Programas Nacionales de Salud/normas , Administración en Salud Pública/normasRESUMEN
Lifelong immunoglobulin replacement is the standard, expensive therapy for severe primary antibody deficiencies. This treatment can be administrated either by intravenous immunoglobulin (IVIG) or subcutaneous infusions (SCIG) and delivered at home or in an out-patient setting. This study aims to determine whether SCIG is cost-effective compared with IVIG from a French social insurance perspective. Because both methods of administration provide similar efficacies, a cost-minimization analysis was performed. First, costs were calculated through a simulation testing different hypothesis on costs drivers. Secondly, costs were estimated on the basis of field data collected by a questionnaire completed by a population of patients suffering from agammaglobulinaemia and hyper-immunoglobulin (Ig)M syndrome. Patients' satisfaction was also documented. Results of the simulation showed that direct medical costs ranged from 19 484 euro for home-based IVIG to 25 583 euro for hospital-based IVIG, with home-based SCIG in between at 24 952 euro per year. Estimations made from field data were found to be different, with significantly higher costs for IVIG. This result was explained mainly by a higher immunoglobulin mean dose prescribed for IVIG. While the theoretical model showed very little difference between SCIG and hospital-based IVIG costs, SCIG appears to be 25% less expensive with field data because of lower doses used in SCIG patients. The reality of the dose difference between both routes of administration needs to be confirmed by further and more specific studies.
Asunto(s)
Agammaglobulinemia/terapia , Síndrome de Inmunodeficiencia con Hiper-IgM/terapia , Inmunoglobulinas Intravenosas/uso terapéutico , Agammaglobulinemia/economía , Agammaglobulinemia/enfermería , Atención Ambulatoria/economía , Estudios de Cohortes , Control de Costos , Costo de Enfermedad , Costos de los Medicamentos , Francia , Gastos en Salud , Servicios de Atención de Salud a Domicilio/economía , Servicios de Atención a Domicilio Provisto por Hospital/economía , Hospitalización/economía , Humanos , Síndrome de Inmunodeficiencia con Hiper-IgM/economía , Síndrome de Inmunodeficiencia con Hiper-IgM/enfermería , Inmunoglobulinas Intravenosas/administración & dosificación , Inmunoglobulinas Intravenosas/economía , Infusiones Intravenosas/economía , Infusiones Subcutáneas/economía , Servicios de Enfermería/economía , Servicio Ambulatorio en Hospital/economía , Satisfacción del Paciente , Transportes/economíaRESUMEN
BACKGROUND: Although common in many countries, anticipated ordering of radiographs by nurses in Accident and Emergency Departments (AEDs) remains illegal in France. Despite this, some evidence suggests that it is implemented in a number of AEDs. AIM: To describe the current state of the practice of anticipated ordering of radiographs by nurses in France. RESULTS AND CONCLUSIONS: Despite a low response rate (21.2%), the findings (prevalence and implementation patterns) stress the urgency of a broad review of this issue in France.
Asunto(s)
Servicio de Urgencia en Hospital/estadística & datos numéricos , Radiografía/enfermería , Derivación y Consulta/estadística & datos numéricos , Francia , Humanos , Motivación , Práctica Profesional , Radiografía/estadística & datos numéricos , Servicio de Radiología en Hospital/estadística & datos numéricosRESUMEN
SETTING: Bleach sedimentation is a method used to increase the diagnostic yield of sputum microscopy for countries with a high prevalence of human immunodeficiency virus (HIV) infection and limited resources. OBJECTIVES: To compare the relative cost-effectiveness of different microscopy approaches in diagnosing tuberculosis (TB) in Kenya. METHODS: An analytical decision tree model including cost and effectiveness measures of 10 combinations of direct (D) and overnight bleach (B) sedimentation microscopy was constructed. Data were drawn from the evaluation of the bleach sedimentation method on two specimens (first on the spot [1] and second morning [2]) from 644 TB suspects in a peripheral health clinic. Incremental cost per smear-positive detected case was measured. Costs included human resources and materials using a micro-costing evaluation. RESULTS: All bleach-based microscopy approaches detected significantly more cases (between 23.3% for B1 and 25.9% for B1+B2) than the conventional D1+D2 approach (21.0%). Cost per tested case ranged between respectively euro 2.7 and euro 4.5 for B1 and B1+D2+B2. B1 and B1+B2 were the most cost-effective approaches. D1+B2 and D1+B1 were good alternatives to avoid using approaches exclusively based on bleach sedimentation microscopy. CONCLUSIONS: Among several effective microscopy approaches used, including sodium hypochlorite sedimentation, only some resulted in a limited increase in the laboratory workload and would be most suitable for programmatic implementation.
Asunto(s)
Microscopía/métodos , Hipoclorito de Sodio/química , Esputo/microbiología , Tuberculosis Pulmonar/diagnóstico , Centrifugación , Análisis Costo-Beneficio , Árboles de Decisión , Humanos , Kenia/epidemiología , Microscopía/economía , Factores de Tiempo , Tuberculosis Pulmonar/epidemiologíaRESUMEN
The MEAH, a French national agency working on health services organization, has led a two-year campaign on safety improvement in radiotherapy centers. The pilot project involved three voluntary French cancer centers in 2005 and 2006. Building on the results of this project, a roll-out campaign has been launched, involving more than 50 additional cancer centers from 2007 and on. This paper presents the results of experiences of these campaigns. Notably, the axes of improvement chosen by professionals, such as risk analysis or use of checklists are discussed.